Tcg Crossover Management is an investment fund managing more than $1.26 trillion ran by Craig Skaling. There are currently 33 companies in Mr. Skaling’s portfolio. The largest investments include Cg Oncology, Inc. and Dyne Therapeutics, together worth $232 billion.
As of 7th August 2024, Tcg Crossover Management’s top holding is 3,570,206 shares of Cg Oncology, Inc. currently worth over $157 billion and making up 12.4% of the portfolio value.
In addition, the fund holds 2,650,150 shares of Dyne Therapeutics worth $75.2 billion, whose value grew 78.0% in the past six months.
The third-largest holding is Astria Therapeutics Inc worth $74.3 billion and the next is Silence Therapeutics plc worth $71.2 billion, with 3,295,350 shares owned.
Currently, Tcg Crossover Management's portfolio is worth at least $1.26 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Tcg Crossover Management office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Craig Skaling serves as the CCO & CFO at Tcg Crossover Management.
In the most recent 13F filing, Tcg Crossover Management revealed that it had opened a new position in
Cg Oncology, Inc. and bought 3,570,206 shares worth $157 billion.
The investment fund also strengthened its position in Dyne Therapeutics by buying
1,000,000 additional shares.
This makes their stake in Dyne Therapeutics total 2,650,150 shares worth $75.2 billion.
Dyne Therapeutics soared 291.9% in the past year.
On the other hand, there are companies that Tcg Crossover Management is getting rid of from its portfolio.
Tcg Crossover Management closed its position in Icosavax Inc on 14th August 2024.
It sold the previously owned 3,703,704 shares for $58.4 billion.
Craig Skaling also disclosed a decreased stake in Structure Therapeutics Inc by 0.2%.
This leaves the value of the investment at $68.5 billion and 1,598,421 shares.
The two most similar investment funds to Tcg Crossover Management are Washington State Investment Board and Ion Asset Management. They manage $959 billion and $958 billion respectively.
Tcg Crossover Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 58.9% of
the total portfolio value.
The fund focuses on investments in the United States as
54.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
6% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $518 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Cg Oncology, Inc. |
Opened
3,570,206
|
$156,732,043,000 | 12.39% |
| Dyne Therapeutics, Inc. |
60.60%
2,650,150
|
$75,237,759,000 | 5.95% |
| Astria Therapeutics Inc |
Opened
5,278,928
|
$74,300,912,000 | 5.87% |
| Silence Therapeutics plc |
56.56%
3,295,350
|
$71,179,560,000 | 5.63% |
| Structure Therapeutics Inc |
24.23%
1,598,421
|
$68,508,324,000 | 5.42% |
| Aerovate Therapeutics Inc |
No change
2,201,274
|
$65,091,672,000 | 5.15% |
| Inhibrx, Inc. |
No change
1,750,387
|
$61,193,530,000 | 4.84% |
| Icosavax Inc |
Closed
3,703,704
|
$58,370,375,000 | |
| Keros Therapeutics, Inc. |
Opened
879,344
|
$58,212,573,000 | 4.60% |
| Geron Corp. |
25.60%
17,391,639
|
$57,392,409,000 | 4.54% |
| Rayzebio, Inc. |
Closed
869,908
|
$54,082,180,000 | |
| Savara Inc |
No change
10,000,000
|
$49,800,000,000 | 3.94% |
| Ocular Therapeutix Inc |
Opened
5,319,148
|
$48,404,247,000 | 3.83% |
| Gracell Biotechnologies Inc. |
Closed
4,514,786
|
$45,328,451,000 | |
| Cogent Biosciences, Inc. |
10.36%
6,214,375
|
$41,760,600,000 | 3.30% |
| Edgewise Therapeutics, Inc. |
Opened
2,272,728
|
$41,454,559,000 | 3.28% |
| Mineralys Therapeutics, Inc. |
Opened
3,185,185
|
$41,120,738,000 | 3.25% |
| Madrigal Pharmaceuticals Inc |
17.03%
149,283
|
$39,864,532,000 | 3.15% |
| Tourmaline Bio Inc |
46.60%
1,477,593
|
$33,836,880,000 | 2.68% |
| Tyra Biosciences Inc |
No change
1,989,103
|
$32,621,289,000 | 2.58% |
| COMPASS Pathways plc |
No change
3,858,000
|
$32,098,560,000 | 2.54% |
| Kura Oncology Inc |
No change
1,423,642
|
$30,366,284,000 | 2.40% |
| Tarsus Pharmaceuticals, Inc. |
30.54%
793,829
|
$28,855,684,000 | 2.28% |
| Adverum Biotechnologies Inc |
Opened
2,008,340
|
$28,397,928,000 | 2.25% |
| Soleno Therapeutivs, Inc. |
Opened
550,000
|
$23,540,000,000 | 1.86% |
| Centessa Pharmaceuticals Plc |
No change
2,040,816
|
$23,061,221,000 | 1.82% |
| Abivax Sa |
No change
1,100,000
|
$15,730,000,000 | 1.24% |
| Vistagen Therapeutics Inc. |
No change
2,676,580
|
$14,132,343,000 | 1.12% |
| KalVista Pharmaceuticals Inc |
65.74%
1,163,356
|
$13,797,402,000 | 1.09% |
| C4 Therapeutics, Inc. |
No change
1,276,574
|
$10,429,610,000 | 0.82% |
| Entrada Therapeutics Inc |
No change
584,955
|
$8,288,812,000 | 0.66% |
| Nurix Therapeutics, Inc. |
Closed
717,654
|
$7,406,189,000 | |
| Taysha Gene Therapies, Inc. |
Closed
2,912,861
|
$5,155,764,000 | |
| An2 Therapeutics, Inc. |
41.93%
1,555,118
|
$5,054,134,000 | 0.40% |
| Kodiak Sciences Inc |
235.89%
899,999
|
$4,733,995,000 | 0.37% |
| Ventyx Biosciences, Inc |
No change
815,724
|
$4,486,482,000 | 0.35% |
| Nektar Therapeutics |
Opened
4,000,000
|
$3,736,800,000 | 0.30% |
| Cabaletta Bio Inc |
82.17%
86,795
|
$1,480,723,000 | 0.12% |
| No transactions found | |||
| Showing first 500 out of 38 holdings | |||